| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Review; Journal Article
- Language: English
- [Endocr Metab Immune Disord Drug Targets] 2022; Vol. 22 (14), pp. 1344-1356.
- MeSH Terms: Cardiovascular Diseases* ; Microbiota* ; Gastrointestinal Microbiome* ; Humans ; Diet ; Immune System
- References: Wang J.; Ji H.; Influence of probiotics on dietary protein digestion and utilization in the gastrointestinal tract. Curr Protein Pept Sci 2019,20(2),125-131. (PMID: 10.2174/138920371966618051710033929769003) ; Lallès J.; Intestinal alkaline phosphatase in the gastrointestinal tract of fish: Biology, ontogeny, and environmental and nutritional modulation. Rev Aquacult 2020,12(2),555-581. (PMID: 10.1111/raq.12340) ; Davila A.M.; Blachier F.; Gotteland M.; Andriamihaja M.; Benetti P.H.; Sanz Y.; Tomé D.; Re-print of “Intestinal luminal nitrogen metabolism: Role of the gut microbiota and consequences for the host”. Pharmacol Res 2013,69(1),114-126. (PMID: 10.1016/j.phrs.2013.01.00323318949) ; Bouter K.E.; van Raalte D.H.; Groen A.K.; Nieuwdorp M.; Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. Gastroenterology 2017,152(7),1671-1678. (PMID: 10.1053/j.gastro.2016.12.04828192102) ; Tlaskalová-Hogenová H.; Stěpánková, R.; Kozáková, H.; Hudcovic, T.; Vannucci, L.; Tučková, L.; Rossmann, P.; Hrnčíř, T.; Kverka, M.; Zákostelská, Z.; Klimešová, K.; Přibylová, J.; Bártová, J.; Sanchez, D.; Fundová, P.; Borovská, D.; Srůtková, D.; Zídek, Z.; Schwarzer, M.; Drastich, P.; Funda, D.P. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: Contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011,8(2),110-120. (PMID: 10.1038/cmi.2010.6721278760) ; Verdugo-Meza A.; Ye J.; Dadlani H.; Ghosh S.; Gibson D.L.; Connecting the dots between inflammatory bowel disease and metabolic syndrome: A focus on gut-derived metabolites. Nutrients 2020,12(5),1434. (PMID: 10.3390/nu1205143432429195) ; Kau A.L.; Ahern P.P.; Griffin N.W.; Goodman A.L.; Gordon J.I.; Human nutrition, the gut microbiome and the immune system. Nature 2011,474(7351),327-336. (PMID: 10.1038/nature1021321677749) ; Goodrich J.K.; Davenport E.R.; Clark A.G.; Ley R.E.; The relationship between the human genome and microbiome comes into view. Annu Rev Genet 2017,51,413-433. (PMID: 10.1146/annurev-genet-110711-15553228934590) ; Jeong Y.; Kim J.W.; You H.J.; Park S.J.; Lee J.; Ju J.H.; Park M.S.; Jin H.; Cho M.L.; Kwon B.; Park S.H.; Ji G.E.; Gut microbial composition and function are altered in patients with early rheumatoid arthritis. J Clin Med 2019,8(5),693. (PMID: 10.3390/jcm805069331100891) ; Sencio V.; Machado M.G.; Trottein F.; The lung-gut axis during viral respiratory infections: The impact of gut dysbiosis on secondary disease outcomes. Mucosal Immunol 2021,14(2),296-304. (PMID: 10.1038/s41385-020-00361-833500564) ; Carding S.; Verbeke K.; Vipond D.T.; Corfe B.M.; Owen L.J.; Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015,26(1),26191. (PMID: 25651997) ; Singh R.K.; Chang H.W.; Yan D.; Lee K.M.; Ucmak D.; Wong K.; Abrouk M.; Farahnik B.; Nakamura M.; Zhu T.H.; Bhutani T.; Liao W.; Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017,15(1),73. (PMID: 10.1186/s12967-017-1175-y28388917) ; Tang W.H.W.; Kitai T.; Hazen S.L.; Gut microbiota in cardiovascular health and disease. Circ Res 2017,120(7),1183-1196. (PMID: 10.1161/CIRCRESAHA.117.30971528360349) ; Savarese G.; Lund L.H.; Global public health burden of heart failure. Card Fail Rev 2017,3(1),7-11. (PMID: 10.15420/cfr.2016:25:228785469) ; World Health Organisation Cardiovasc. Dis., 2017. Available from:. ; Velasquez M.T.; Centron P.; Barrows I.; Dwivedi R.; Raj D.S.; Gut microbiota and cardiovascular uremic toxicities. Toxins (Basel) 2018,10(7),287. (PMID: 10.3390/toxins1007028729997362) ; Ahmad A.F.; Ward N.C.; Dwivedi G.; The gut microbiome and heart failure. Curr Opin Cardiol 2019,34(2),225-232. (PMID: 10.1097/HCO.000000000000059830575647) ; Sekirov I.; Russell S.L.; Antunes L.C.M.; Finlay B.B.; Gut microbiota in health and disease. Physiol Rev 2010,90(3),859-904. (PMID: 10.1152/physrev.00045.200920664075) ; Camilleri M.; Lyle B.J.; Madsen K.L.; Sonnenburg J.; Verbeke K.; Wu G.D.; Role for diet in normal gut barrier function: Developing guidance within the framework of food-labeling regulations. Am J Physiol Gastrointest Liver Physiol 2019,317(1),G17-G39. (PMID: 10.1152/ajpgi.00063.201931125257) ; Sircana A.; De Michieli F.; Parente R.; Framarin L.; Leone N.; Berrutti M.; Paschetta E.; Bongiovanni D.; Musso G.; Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacol Res 2019,144,390-408. (PMID: 10.1016/j.phrs.2018.01.01329378252) ; Khosravi A.; Yáñez A.; Price J.G.; Chow A.; Merad M.; Goodridge H.S.; Mazmanian S.K.; Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 2014,15(3),374-381. (PMID: 10.1016/j.chom.2014.02.00624629343) ; Belizário J.E.; Faintuch J.; Microbiome and gut dysbiosis. In: Silvestre, R.; Torrado, E.; Eds. Metabolic Interaction in Infection Springer: Cham, 2018, pp. 459-476. (PMID: 10.1007/978-3-319-74932-7_13) ; Sandek A.; Bauditz J.; Swidsinski A.; Buhner S.; Weber-Eibel J.; von Haehling S.; Schroedl W.; Karhausen T.; Doehner W.; Rauchhaus M.; Poole-Wilson P.; Volk H.D.; Lochs H.; Anker S.D.; Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007,50(16),1561-1569. (PMID: 10.1016/j.jacc.2007.07.01617936155) ; Sandek A.; Haehling S.D.A.; von, S The gut and intestinal bacteria in chronic heart failure. Current Drug Metabolism 2009,10,22-28. ; Charlet R.; Bortolus C.; Barbet M.; Sendid B.; Jawhara S.; A decrease in anaerobic bacteria promotes Candida glabrata overgrowth while β-glucan treatment restores the gut microbiota and attenuates colitis. Gut Pathog 2018,10(1),50. (PMID: 10.1186/s13099-018-0277-230524506) ; Yu M.; Jia H.; Zhou C.; Yang Y.; Zhao Y.; Yang M.; Zou Z.; Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics. J Pharm Biomed Anal 2017,138,231-239. (PMID: 10.1016/j.jpba.2017.02.00828219800) ; Kamo T.; Akazawa H.; Suda W.; Saga-Kamo A.; Shimizu Y.; Yagi H.; Liu Q.; Nomura S.; Naito A.T.; Takeda N.; Harada M.; Toko H.; Kumagai H.; Ikeda Y.; Takimoto E.; Suzuki J.I.; Honda K.; Morita H.; Hattori M.; Komuro I.; Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One 2017,12(3),e0174099. (PMID: 10.1371/journal.pone.017409928328981) ; Tang W.H.W.; Wang Z.; Levison B.S.; Koeth R.A.; Britt E.B.; Fu X.; Wu Y.; Hazen S.L.; Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013,368(17),1575-1584. (PMID: 10.1056/NEJMoa110940023614584) ; Tang W.H.W.; Wang Z.; Fan Y.; Levison B.; Hazen J.E.; Donahue L.M.; Wu Y.; Hazen S.L.; Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J Am Coll Cardiol 2014,64(18),1908-1914. (PMID: 10.1016/j.jacc.2014.02.61725444145) ; Shimokawa H.; Miura M.; Nochioka K.; Sakata Y.; Heart failure as a general pandemic in Asia. Eur J Heart Fail 2015,17(9),884-892. (PMID: 10.1002/ejhf.31926222508) ; Karlsson F.H.; Fåk F.; Nookaew I.; Tremaroli V.; Fagerberg B.; Petranovic D.; Bäckhed F.; Nielsen J.; Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012,3,1245. (PMID: 10.1038/ncomms226623212374) ; Emoto T.; Yamashita T.; Sasaki N.; Hirota Y.; Hayashi T.; So A.; Kasahara K.; Yodoi K.; Matsumoto T.; Mizoguchi T.; Ogawa W.; Hirata K.; Analysis of gut microbiota in coronary artery disease patients: A possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb 2016,23(8),908-921. (PMID: 10.5551/jat.3267226947598) ; Jie Z.; Xia H.; Zhong S.L.; Feng Q.; Li S.; Liang S.; Zhong H.; Liu Z.; Gao Y.; Zhao H.; Zhang D.; Su Z.; Fang Z.; Lan Z.; Li J.; Xiao L.; Li J.; Li R.; Li X.; Li F.; Ren H.; Huang Y.; Peng Y.; Li G.; Wen B.; Dong B.; Chen J.Y.; Geng Q.S.; Zhang Z.W.; Yang H.; Wang J.; Wang J.; Zhang X.; Madsen L.; Brix S.; Ning G.; Xu X.; Liu X.; Hou Y.; Jia H.; He K.; Kristiansen K.; The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017,8(1),845. (PMID: 10.1038/s41467-017-00900-129018189) ; Fåk F.; Tremaroli V.; Bergström G.; Bäckhed F.; Oral microbiota in patients with atherosclerosis. Atherosclerosis 2015,243(2),573-578. (PMID: 10.1016/j.atherosclerosis.2015.10.09726536303) ; Lv L.X.; Fang D.Q.; Shi D.; Chen D.Y.; Yan R.; Zhu Y.X.; Chen Y.F.; Shao L.; Guo F.F.; Wu W.R.; Li A.; Shi H.Y.; Jiang X.W.; Jiang H.Y.; Xiao Y.H.; Zheng S.S.; Li L.J.; Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol 2016,18(7),2272-2286. (PMID: 10.1111/1462-2920.1340127243236) ; Jonsson A.L.; Bäckhed F.; Role of gut microbiota in atherosclerosis. Nat Rev Cardiol 2017,14(2),79-87. (PMID: 10.1038/nrcardio.2016.18327905479) ; Priyamvara A.; Dey A.K.; Bandyopadhyay D.; Katikineni V.; Zaghlol R.; Basyal B.; Barssoum K.; Amarin R.; Bhatt D.L.; Lavie C.J.; Periodontal inflammation and the risk of cardiovascular disease. Curr Atheroscler Rep 2020,22(7),28. (PMID: 10.1007/s11883-020-00848-632514778) ; Astbury S.; Atallah E.; Vijay A.; Aithal G.P.; Grove J.I.; Valdes A.M.; Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes 2020,11(3),569-580. (PMID: 10.1080/19490976.2019.168186131696774) ; Rinninella E.; Raoul P.; Cintoni M.; Franceschi F.; Miggiano G.A.D.; Gasbarrini A.; Mele M.C.; What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 2019,7(1),14. (PMID: 10.3390/microorganisms701001430634578) ; Amabebe E.; Robert F.O.; Agbalalah T.; Orubu E.S.F.; Microbial dysbiosis-induced obesity: Role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr 2020,123(10),1127-1137. (PMID: 10.1017/S000711452000038032008579) ; Cox A.J.; West N.P.; Cripps A.W.; Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2015,3(3),207-215. (PMID: 10.1016/S2213-8587(14)70134-225066177) ; Tilg H.; Zmora N.; Adolph T.E.; Elinav E.; The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020,20(1),40-54. (PMID: 10.1038/s41577-019-0198-431388093) ; Komaroff A.L.; The microbiome and risk for atherosclerosis. JAMA 2018,319(23),2381-2382. (PMID: 10.1001/jama.2018.524029800043) ; Zinöcker M.K.; Lindseth I.A.; The Western diet–microbiome-host interaction and its role in metabolic disease. Nutrients 2018,10(3),365. (PMID: 10.3390/nu1003036529562591) ; De Filippis F.; Pellegrini N.; Vannini L.; Jeffery I.B.; La Storia A.; Laghi L.; Serrazanetti D.I.; Di Cagno R.; Ferrocino I.; Lazzi C.; Turroni S.; Cocolin L.; Brigidi P.; Neviani E.; Gobbetti M.; O’Toole P.W.; Ercolini D.; High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 2016,65(11),1812-1821. (PMID: 10.1136/gutjnl-2015-30995726416813) ; Morera L.P.; Marchiori G.N.; Medrano L.A.; Defagó M.D.; Stress, dietary patterns and cardiovascular disease: A mini-review. Front Neurosci 2019,13,1226. (PMID: 10.3389/fnins.2019.0122631780892) ; Laugerette F.; Furet J.P.; Debard C.; Daira P.; Loizon E.; Géloën A.; Soulage C.O.; Simonet C.; Lefils-Lacourtablaise J.; Bernoud-Hubac N.; Bodennec J.; Peretti N.; Vidal H.; Michalski M.C.; Oil composition of high-fat diet affects metabolic inflammation differently in connection with endotoxin receptors in mice. Am J Physiol Endocrinol Metab 2012,302(3),E374-E386. (PMID: 10.1152/ajpendo.00314.201122094473) ; Forkosh E.; Ilan Y.; The heart-gut axis: New target for atherosclerosis and congestive heart failure therapy. Open Heart 2019,6(1),e000993. (PMID: 10.1136/openhrt-2018-00099331168383) ; Tang W.H.W.; Bäckhed F.; Landmesser U.; Hazen S.L.; Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. J Am Coll Cardiol 2019,73(16),2089-2105. (PMID: 10.1016/j.jacc.2019.03.02431023434) ; Scarmozzino F.; Poli A.; Visioli F.; Microbiota and cardiovascular disease risk: A scoping review. Pharmacol Res 2020,159,104952. (PMID: 10.1016/j.phrs.2020.10495232492487) ; Tang W.H.W.; Hazen S.L.; The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014,124(10),4204-4211. (PMID: 10.1172/JCI7233125271725) ; Roberts A.B.; Gu X.; Buffa J.A.; Hurd A.G.; Wang Z.; Zhu W.; Gupta N.; Skye S.M.; Cody D.B.; Levison B.S.; Barrington W.T.; Russell M.W.; Reed J.M.; Duzan A.; Lang J.M.; Fu X.; Li L.; Myers A.J.; Rachakonda S.; DiDonato J.A.; Brown J.M.; Gogonea V.; Lusis A.J.; Garcia-Garcia J.C.; Hazen S.L.; Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 2018,24(9),1407-1417. (PMID: 10.1038/s41591-018-0128-130082863) ; Wang Z.; Bergeron N.; Levison B.S.; Li X.S.; Chiu S.; Jia X.; Koeth R.A.; Li L.; Wu Y.; Tang W.H.W.; Krauss R.M.; Hazen S.L.; Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J 2019,40(7),583-594. (PMID: 10.1093/eurheartj/ehy79930535398) ; Chen X.; Li H.Y.; Hu X.M.; Zhang Y.; Zhang S.Y.; Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chin Med J (Engl) 2019,132(15),1843-1855. (PMID: 10.1097/CM9.000000000000033031306229) ; Zeisel S.H.; Warrier M.; Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annu Rev Nutr 2017,37,157-181. (PMID: 10.1146/annurev-nutr-071816-06473228715991) ; Canyelles M.; Tondo M.; Cedó L.; Farràs M.; Escolà-Gil J.C.; Blanco-Vaca F.; Trimethylamine N-oxide: A link among diet, gut microbiota, gene regulation of liver and intestine cholesterol homeostasis and HDL function. Int J Mol Sci 2018,19(10),3228. (PMID: 10.3390/ijms1910322830347638) ; Van Parys A.; Lysne V.; Øyen J.; Dierkes J.; Nygård O.; No effect of plasma trimethylamine N-Oxide (TMAO) and plasma trimethyllysine (TML) on the association between choline intake and acute myocardial infarction risk in patients with stable angina pectoris. Human Nutr Metabol 2020,21,200112. (PMID: 10.1016/j.hnm.2020.200112) ; Tang W.H.W.; Hazen S.L.; Microbiome, trimethylamine N-oxide, and cardiometabolic disease. Transl Res 2017,179,108-115. (PMID: 10.1016/j.trsl.2016.07.00727490453) ; Nowiński, A.; Ufnal, M. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases? Nutrition 2018,46,7-12. (PMID: 10.1016/j.nut.2017.08.00129290360) ; Trøseid M.; Ueland T.; Hov J.R.; Svardal A.; Gregersen I.; Dahl C.P.; Aakhus S.; Gude E.; Bjørndal B.; Halvorsen B.; Karlsen T.H.; Aukrust P.; Gullestad L.; Berge R.K.; Yndestad A.; Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med 2015,277(6),717-726. (PMID: 10.1111/joim.1232825382824) ; Bach Knudsen K.E.; Lærke H.N.; Hedemann M.S.; Nielsen T.S.; Ingerslev A.K.; Gundelund Nielsen D.S.; Theil P.K.; Purup S.; Hald S.; Schioldan A.G.; Marco M.L.; Gregersen S.; Hermansen K.; Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients 2018,10(10),1499. (PMID: 10.3390/nu1010149930322146) ; Parada Venegas D.; De la Fuente M.K.; Landskron G.; González M.J.; Quera R.; Dijkstra G.; Harmsen H.J.M.; Faber K.N.; Hermoso M.A.; Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 2019,10,277. (PMID: 10.3389/fimmu.2019.0027730915065) ; Chen J.; Vitetta L.; The role of butyrate in attenuating pathobiont-induced hyperinflammation. Immune Netw 2020,20(2),e15. (PMID: 10.4110/in.2020.20.e1532395367) ; Bischoff S.C.; Barbara G.; Buurman W.; Ockhuizen T.; Schulzke J.D.; Serino M.; Tilg H.; Watson A.; Wells J.M.; Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol 2014,14(1),189. (PMID: 10.1186/s12876-014-0189-725407511) ; Trøseid M.; Andersen G.Ø.; Broch K.; Hov J.R.; The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine 2020,52,102649. (PMID: 10.1016/j.ebiom.2020.10264932062353) ; Yoo J.Y.; Groer M.; Dutra S.V.O.; Sarkar A.; McSkimming D.I.; Gut microbiota and immune system interactions. Microorganisms 2020,8(10),1587. (PMID: 10.3390/microorganisms810158733076307) ; Fang W.; Xue H.; Chen X.; Chen K.; Ling W.; Supplementation with sodium butyrate modulates the composition of the gut microbiota and ameliorates high-fat diet-induced obesity in mice. J Nutr 2019,149(5),747-754. (PMID: 10.1093/jn/nxy32431004166) ; Mafra D.; Lobo J.C.; Barros A.F.; Koppe L.; Vaziri N.D.; Fouque D.; Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 2014,9(3),399-410. (PMID: 10.2217/fmb.13.16524762311) ; Mirzaeian S.; Saraf-Bank S.; Entezari M.H.; Hekmatdoost A.; Feizi A.; Atapour A.; Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition 2020,73,110713. (PMID: 10.1016/j.nut.2019.11071332120316) ; Filipska I.; Winiarska A.; Knysak M.; Stompór T.; Contribution of gut microbiota-derived uremic toxins to the cardiovascular system mineralization. Toxins (Basel) 2021,13(4),274. (PMID: 10.3390/toxins1304027433920096) ; Sallée M.; Dou L.; Cerini C.; Poitevin S.; Brunet P.; Burtey S.; The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: A new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel) 2014,6(3),934-949. (PMID: 10.3390/toxins603093424599232) ; Lekawanvijit S.; Cardiotoxicity of uremic toxins: A driver of cardiorenal syndrome. Toxins (Basel) 2018,10(9),352. (PMID: 10.3390/toxins1009035230200452) ; Mishra A.K.; Dubey V.; Ghosh A.R.; Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism 2016,65(1),48-65. (PMID: 10.1016/j.metabol.2015.10.00826683796) ; Chambers E.S.; Preston T.; Frost G.; Morrison D.J.; Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep 2018,7(4),198-206. (PMID: 10.1007/s13668-018-0248-830264354) ; Sente T.; Van Berendoncks A.M.; Hoymans V.Y.; Vrints C.J.; Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle 2016,7(3),261-274. (PMID: 10.1002/jcsm.1208627239409) ; Wang Y.; Ma X.L.; Lau W.B.; Cardiovascular adiponectin resistance: The critical role of adiponectin receptor modification. Trends Endocrinol Metab 2017,28(7),519-530. (PMID: 10.1016/j.tem.2017.03.00428473178) ; Luedde M.; Winkler T.; Heinsen F.A.; Rühlemann M.C.; Spehlmann M.E.; Bajrovic A.; Lieb W.; Franke A.; Ott S.J.; Frey N.; Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail 2017,4(3),282-290. (PMID: 10.1002/ehf2.1215528772054) ; Cui X.; Ye L.; Li J.; Jin L.; Wang W.; Li S.; Bao M.; Wu S.; Li L.; Geng B.; Zhou X.; Zhang J.; Cai J.; Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 2018,8(1),635. (PMID: 10.1038/s41598-017-18756-229330424) ; Pasini E.; Aquilani R.; Testa C.; Baiardi P.; Angioletti S.; Boschi F.; Verri M.; Dioguardi F.; Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 2016,4(3),220-227. (PMID: 10.1016/j.jchf.2015.10.00926682791) ; Luedde M.; Spehlmann M.E.; Frey N.; Progress in heart failure treatment in Germany. Clin Res Cardiol 2018,107(2)(Suppl. 2),105-113. (PMID: 10.1007/s00392-018-1317-029968196) ; Sánchez B.; Delgado S.; Blanco-Míguez A.; Lourenço A.; Gueimonde M.; Margolles A.; Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res 2017,61(1),1600240. (PMID: 10.1002/mnfr.20160024027500859) ; Martín R.; Langella P.; Emerging health concepts in the probiotics field: Streamlining the definitions. Front Microbiol 2019,10,1047. (PMID: 10.3389/fmicb.2019.0104731164874) ; Kothari D.; Patel S.; Kim S.K.; Probiotic supplements might not be universally-effective and safe: A review. Biomed Pharmacother 2019,111,537-547. (PMID: 10.1016/j.biopha.2018.12.10430597307) ; Voidarou C.; Antoniadou, Μ; Rozos, G.; Tzora, A.; Skoufos, I.; Varzakas, T.; Lagiou, A.; Bezirtzoglou, E. Fermentative foods: Microbiology, biochemistry, potential human health benefits and public health issues. Foods 2020,10(1),69. (PMID: 10.3390/foods1001006933396397) ; Solas M.; Milagro F.I.; Ramírez M.J.; Martínez J.A.; Inflammation and gut-brain axis link obesity to cognitive dysfunction: Plausible pharmacological interventions. Curr Opin Pharmacol 2017,37,87-92. (PMID: 10.1016/j.coph.2017.10.00529107872) ; Oniszczuk A.; Oniszczuk T.; Gancarz M.; Szymańska, J. Role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases. Molecules 2021,26(4),1172. (PMID: 10.3390/molecules2604117233671813) ; Kleerebezem M.; Vaughan E.E.; Probiotic and gut lactobacilli and bifidobacteria: Molecular approaches to study diversity and activity. Annu Rev Microbiol 2009,63,269-290. (PMID: 10.1146/annurev.micro.091208.07334119575569) ; Sekhon B.S.; Jairath S.; Prebiotics, probiotics and synbiotics: An overview. J Pharm Edu Res 2010,1(2),13-36. ; Markowiak P.; Śliżewska, K. The role of probiotics, prebiotics and synbiotics in animal nutrition. Gut Pathog 2018,10(1),21. (PMID: 10.1186/s13099-018-0250-029930711) ; Sanders M.E.; Merenstein D.J.; Reid G.; Gibson G.R.; Rastall R.A.; Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat Rev Gastroenterol Hepatol 2019,16(10),605-616. (PMID: 10.1038/s41575-019-0173-331296969) ; Liu Y.; Alookaran J.J.; Rhoads J.M.; Probiotics in autoimmune and inflammatory disorders. Nutrients 2018,10(10),1537. (PMID: 10.3390/nu1010153730340338) ; Moludi J.; Alizadeh M.; Davari M.; Golmohammadi A.; Maleki V.; The efficacy and safety of probiotics intervention in attenuating cardiac remodeling following myocardial infraction: Literature review and study protocol for a randomized, double-blinded, placebo controlled trial. Contemp Clin Trials Commun 2019,15,100364. (PMID: 10.1016/j.conctc.2019.10036431193187) ; Gan X.T.; Ettinger G.; Huang C.X.; Burton J.P.; Haist J.V.; Rajapurohitam V.; Sidaway J.E.; Martin G.; Gloor G.B.; Swann J.R.; Reid G.; Karmazyn M.; Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail 2014,7(3),491-499. (PMID: 10.1161/CIRCHEARTFAILURE.113.00097824625365) ; Lam V.; Su J.; Koprowski S.; Hsu A.; Tweddell J.S.; Rafiee P.; Gross G.J.; Salzman N.H.; Baker J.E.; Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012,26(4),1727-1735. (PMID: 10.1096/fj.11-19792122247331) ; Costanza A.C.; Moscavitch S.D.; Faria Neto H.C.C.; Mesquita E.T.; Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial. Int J Cardiol 2015,179,348-350. (PMID: 10.1016/j.ijcard.2014.11.034) ; Gómez-Guzmán M.; Toral M.; Romero M.; Jiménez R.; Galindo P.; Sánchez M.; Zarzuelo M.J.; Olivares M.; Gálvez J.; Duarte J.; Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res 2015,59(11),2326-2336. (PMID: 10.1002/mnfr.20150029026255877) ; Sarkar D.; Ankolekar C.; Shetty K.; Functional food components for preventing and combating type 2 diabetes. In: Patil, B.S.; Jayaprakasha, G.K.; Murthy, K.N.C.; Seeram, N.P.; Eds. Emerging Trends in Dietary Components for Preventing and Combating Disease ACS Publications: Wasgington DC, 2012, pp. 345-374. (PMID: 10.1021/bk-2012-1093.ch020) ; Saad B.; Zaid H.; Shanak S.; Kadan S.; Anti-Diabetes and Anti-Obesity Medicinal Plants and Phytochemicals 2017. (PMID: 10.1007/978-3-319-54102-0) ; De Sousa V.M.C.; Dos Santos E.V.; Sgarbieri V.C.; The importance of prebiotics in functional foods and clinical practice. Food Nutr Sci 2011,2(2). ; George Kerry R.; Patra J.K.; Gouda S.; Park Y.; Shin H.S.; Das G.; Benefaction of probiotics for human health: A review. J Food Drug Anal 2018,26(3),927-939. (PMID: 10.1016/j.jfda.2018.01.00229976412) ; Macfarlane G.T.; Macfarlane S.; Fermentation in the human large intestine: Its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol 2011,45(Suppl.),S120-S127. (PMID: 10.1097/MCG.0b013e31822fecfe21992950) ; Ashaolu T.J.; Ashaolu J.O.; Adeyeye S.A.O.; Fermentation of prebiotics by human colonic microbiota in vitro and short-chain fatty acids production: A critical review. J Appl Microbiol 2021,130(3),677-687. (PMID: 10.1111/jam.1484332892434) ; Damaskos D.; Kolios G.; Probiotics and prebiotics in inflammatory bowel disease: Microflora ‘on the scope’. Br J Clin Pharmacol 2008,65(4),453-467. (PMID: 10.1111/j.1365-2125.2008.03096.x18279467) ; Mohanty D.; Misra S.; Mohapatra S.; Sahu P.S.; Prebiotics and synbiotics: Recent concepts in nutrition. Food Biosci 2018,26,152-160. (PMID: 10.1016/j.fbio.2018.10.008) ; Palai S.; Derecho C.M.P.; Kesh S.S.; Egbuna C.; Onyeike P.C.; Prebiotics, probiotics, synbiotics and its importance in the management of diseases. In: Egbuna, C.; Dable Tupas, G.; Eds. Functional Foods and Nutraceuticals Springer Cham,2020,173-196. (PMID: 10.1007/978-3-030-42319-3_10) ; Marques F.Z.; Nelson E.; Chu P.Y.; Horlock D.; Fiedler A.; Ziemann M.; Tan J.K.; Kuruppu S.; Rajapakse N.W.; El-Osta A.; Mackay C.R.; Kaye D.M.; High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 2017,135(10),964-977. (PMID: 10.1161/CIRCULATIONAHA.116.02454527927713) ; Patel B.; Kumar P.; Banerjee R.; Basu M.; Pal A.; Samanta M.; Das S.; Lactobacillus acidophilus attenuates Aeromonas hydrophila induced cytotoxicity in catla thymus macrophages by modulating oxidative stress and inflammation. Mol Immunol 2016,75,69-83. (PMID: 10.1016/j.molimm.2016.05.01227262084) ; Guarino M.P.L.; Altomare A.; Emerenziani S.; Di Rosa C.; Ribolsi M.; Balestrieri P.; Iovino P.; Rocchi G.; Cicala M.; Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults. Nutrients 2020,12(4),1037. (PMID: 10.3390/nu1204103732283802) ; Netto B.D.M.; Bettini S.C.; Clemente A.P.G.; Ferreira J.P.; Boritza K.; Souza, Sde.F.; Von der Heyde, M.E.; Earthman, C.P.; Dâmaso, A.R. Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg 2015,25(6),1010-1018. (PMID: 10.1007/s11695-014-1484-725403776) ; Ashrafian H.; Li J.V.; Spagou K.; Harling L.; Masson P.; Darzi A.; Nicholson J.K.; Holmes E.; Athanasiou T.; Bariatric surgery modulates circulating and cardiac metabolites. J Proteome Res 2014,13(2),570-580. (PMID: 10.1021/pr400748f24279706) ; Wang Y.H.; Current progress of research on intestinal bacterial translocation. Microb Pathog 2021,152,104652. (PMID: 10.1016/j.micpath.2020.10465233249165) ; Li J.; Lin S.; Vanhoutte P.M.; Woo C.W.; Xu A.; Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/- Mice. Circulation 2016,133(24),2434-2446. (PMID: 10.1161/CIRCULATIONAHA.115.01964527143680) ; Branchereau M.; Burcelin R.; Heymes C.; The gut microbiome and heart failure: A better gut for a better heart. Rev Endocr Metab Disord 2019,20(4),407-414. (PMID: 10.1007/s11154-019-09519-731705258) ; Pamer E.G.; Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016,352(6285),535-538. (PMID: 10.1126/science.aad9382) ; Du Y.; Li X.; Su C.; Wang L.; Jiang J.; Hong B.; The human gut microbiome - a new and exciting avenue in cardiovascular drug discovery. Expert Opin Drug Discov 2019,14(10),1037-1052. (PMID: 10.1080/17460441.2019.163890931315489) ; Wang Z.; Roberts A.B.; Buffa J.A.; Levison B.S.; Zhu W.; Org E.; Gu X.; Huang Y.; Zamanian-Daryoush M.; Culley M.K.; DiDonato A.J.; Fu X.; Hazen J.E.; Krajcik D.; DiDonato J.A.; Lusis A.J.; Hazen S.L.; Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015,163(7),1585-1595. (PMID: 10.1016/j.cell.2015.11.05526687352) ; Singh V.; Yeoh B.S.; Vijay-Kumar M.; Gut microbiome as a novel cardiovascular therapeutic target. Curr Opin Pharmacol 2016,27,8-12. (PMID: 10.1016/j.coph.2016.01.00226828626) ; de Groot P.F.; Frissen M.N.; de Clercq N.C.; Nieuwdorp M.; Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes 2017,8(3),253-267. (PMID: 10.1080/19490976.2017.129322428609252) ; Vrieze A.; Van Nood E.; Holleman F.; Salojärvi J.; Kootte R.S.; Bartelsman J.F.W.M.; Dallinga-Thie G.M.; Ackermans M.T.; Serlie M.J.; Oozeer R.; Derrien M.; Druesne A.; Van Hylckama Vlieg J.E.; Bloks V.W.; Groen A.K.; Heilig H.G.; Zoetendal E.G.; Stroes E.S.; de Vos W.M.; Hoekstra J.B.; Nieuwdorp M.; Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012,143(4),913-6.e7. (PMID: 10.1053/j.gastro.2012.06.03122728514) ; Brown J.M.; Hazen S.L.; The gut microbial endocrine organ: Bacterially derived signals driving cardiometabolic diseases. Annu Rev Med 2015,66,343-359. (PMID: 10.1146/annurev-med-060513-09320525587655) ; Fan Y.; Pedersen O.; Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021,19(1),55-71. (PMID: 32887946) ; Currò D.; The role of gut microbiota in the modulation of drug action: A focus on some clinically significant issues. Expert Rev Clin Pharmacol 2018,11(2),171-183. (PMID: 10.1080/17512433.2018.141459829210311) ; Zhang J.; Zhang J.; Wang R.; Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 2018,50(3),357-368. (PMID: 10.1080/03602532.2018.149764730227749) ; Toghi M.; Bitarafan S.; Simvastatin therapy in multiple sclerosis patients with respect to gut microbiome-friend or foe? J Neuroimmune Pharmacol 2019,14(4),531-533. (PMID: 10.1007/s11481-019-09881-y31628587) ; Liu Y.; Song X.; Zhou H.; Zhou X.; Xia Y.; Dong X.; Zhong W.; Tang S.; Wang L.; Wen S.; Xiao J.; Tang L.; Gut microbiome associates with lipid-lowering effect of rosuvastatin in vivo. Front Microbiol 2018,9,530. (PMID: 10.3389/fmicb.2018.0053029623075) ; Dias A.M.; Cordeiro G.; Estevinho M.M.; Veiga R.; Figueira L.; Reina-Couto M.; Magro F.; Gut bacterial microbiome composition and statin intake-A systematic review. Pharmacol Res Perspect 2020,8(3),e00601. ; Moludi J.; Saiedi S.; Ebrahimi B.; Alizadeh M.; Khajebishak Y.; Ghadimi S.S.; Probiotics supplementation on cardiac remodeling following myocardial infarction: A single-center double-blind clinical study. J Cardiovasc Transl Res 2021,14(2),299-307. (PMID: 10.1007/s12265-020-10052-132681453)
- Contributed Indexing: Keywords: Gut microbiome; cardiovascular disease; drugs; gut dysbiosis; heart failure; metabolism; synbiotics
- Entry Date(s): Date Created: 20220628 Date Completed: 20221221 Latest Revision: 20221222
- Update Code: 20231215
|
